Efficacy and Clinical Outcomes of Levosimendan in E-CPR

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-20

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation. Literature has demonstrated that ECMO initiated during advanced cardiopulmonary life support may confer superior survival rates with acceptable survival and a relatively low incidence of significant neurologic impairment. Levosimendan has not been investigated in patients with cardiac arrest who underwent Extracorporeal CPR (E-CPR). The current study aims to examine whether levosimendan use in the aforementioned patient population could improve survival and ECMO parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest

NCT05956431

Heart Arrest

UNKNOWN PHASE4

LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients

NCT04728932

Cardiogenic Shock Extracorporeal Membrane Oxygenation Complication

COMPLETED PHASE3

Cardiopulmonary Resuscitation Performance of Professional Rescuers With a New Defibrillation Algorithm

NCT04691089

Cardiac Arrest, Sudden Ventricular Tachycardia Ventricular Fibrillation +1 more

COMPLETED

To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients

NCT01665755

Cardiac Event Sudden Cardiac Death Death +2 more

COMPLETED NA

Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB

NCT03614169

Heart Failure With Reduced Ejection Fraction Left Bundle-Branch Block

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiogenic Shock Extracorporeal Membrane Oxygenation Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levosimendan

examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalized patients ≥ 18 years of age at the time of E-CPR use
* Patients suffered cardiac arrest (IHCA or OHCA)
* Patients received VA-ECMO for E-CPR
* Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Exclusion Criteria

* Patients with incomplete key data
* Criteria as per HMC's Extracorporeal Membrane Oxygenation (ECMO) for Cardiac Arrest (E-CPR) clinical practice guidelines (attached with the study protocol)

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No